Ultrasound-based skin tightening is marketed as a non-invasive, no-downtime alternative to surgical lifting. Two platforms dominate the US market: Ultherapy (microfocused ultrasound with visualization, made by Merz) and Sofwave (synchronous ultrasound parallel beam technology, made by Sofwave Medical). Both are FDA-cleared Class II devices — meaning they entered the market through the 510(k) pathway by demonstrating substantial equivalence to previously cleared devices, not through new clinical trials.
Patients often assume that "FDA cleared" means the device has been comprehensively tested for safety. The FDA's MAUDE (Manufacturer and User Facility Device Experience) database offers a different perspective. MAUDE captures adverse event reports submitted voluntarily by patients and providers, and mandatorily by manufacturers and user facilities. It is a passive surveillance system with known underreporting, so the reports that appear represent a fraction of actual events.
An analysis of 223 adverse event reports under FDA product code OHV ("Focused Ultrasound for Tissue Heat or Mechanical Cellular Disruption") — received between December 2012 and May 2026 — reveals the injury patterns, device-specific trends, and provider-side factors that the marketing rarely mentions.
The dataset at a glance
| Metric | Count |
|---|---|
| Total MAUDE reports (OHV) | 223 |
| Injury reports | 204 (91%) |
| Malfunction reports | 18 (8%) |
| Death reports | 0 |
| Other / no answer | 1 |
| Reporting period | Dec 2012 – May 2026 |
The overwhelming majority of reports (91%) describe patient injuries. The 18 malfunction reports describe device technical issues — transducer failures, energy-delivery errors, software problems — some of which occurred during active treatment.
Ultherapy: 160 reports over 14 years
Ultherapy (marketed under various brand names including "Ulthera System," "Ulthera Aesthetic Ultrasound System," and "Ultherapy") accounts for 160 of 223 reports (72%). It is the longest-marketed ultrasound skin-tightening device in the US, having received its initial FDA clearance in 2009 for brow lift, with subsequent clearances for face, neck, décolleté, and body.
Year-over-year trend
| Year | Ultherapy reports |
|---|---|
| 2013 | 6 |
| 2014 | 10 |
| 2015 | 13 |
| 2016 | 21 |
| 2017 | 24 |
| 2018 | 7 |
| 2019 | 15 |
| 2020 | 5 |
| 2021 | 19 |
| 2022 | 8 |
| 2023 | 12 |
| 2024 | 10 |
| 2025 | 8 |
| 2026 (Jan–May) | 2 |
Reports peaked in 2016–2017 (21 and 24 respectively), which coincides with the period when Ultherapy expanded its cleared indications beyond brow lift to include the face, neck, and décolleté — dramatically expanding the treatable population. A second notable cluster appeared in 2021 (19 reports), during the post-pandemic treatment boom.
The declining numbers from 2022 onward may reflect improved provider experience with the device, changes in reporting patterns, or market share shifts toward newer platforms like Sofwave.
Reported injury types
The MAUDE reports for Ultherapy describe a range of injuries, consistent with what the published literature has documented:
- Lipoatrophy (fat loss) — the most discussed Ultherapy complication. Ultrasound energy delivered too deeply can damage subcutaneous fat pads, causing facial hollowing or contour irregularities. A 2025 systematic review by Humphrey et al. in Dermatologic Surgery identified lipoatrophy as one of the most frequently reported serious adverse events in the MAUDE data for Ultherapy.
- Neurologic symptoms — including nerve damage, focal numbness, dysesthesia (altered sensation), and ptosis (drooping of the eyelid). These are thought to occur when ultrasound energy affects superficial facial nerves.
- Scarring and burns — thermal injury to the skin surface when energy settings or coupling are inadequate.
- Prolonged pain and swelling — some reports describe pain, edema, or erythema lasting weeks to months beyond the expected recovery period.
The Humphrey et al. review analyzed 106 MAUDE records specifically for Ultherapy and found that lipoatrophy, neurologic sequelae, and scarring were the most frequently reported serious adverse events. By contrast, the peer-reviewed literature (covering 506 patients across 19 studies) documented mostly transient edema, erythema, and post-procedural pain, with only one case of subcutaneous atrophy — a gap that reflects the well-known underreporting of complications in clinical trials versus passive surveillance data.
Sofwave: rapid report growth in 2025
Sofwave, cleared by the FDA in 2020 for improving facial lines and wrinkles, accounts for 16 of 223 reports (7%). While the total count is smaller than Ultherapy's, the trend is striking:
| Year | Sofwave reports |
|---|---|
| 2022 | 4 |
| 2024 | 1 |
| 2025 | 10 |
| 2026 (Jan–May) | 1 |
Ten of 16 Sofwave reports were received in 2025 alone — a year in which Sofwave's market presence expanded significantly. The company reported its first quarterly net income ($1.5 million on $21 million revenue) in Q2 2025, with a 75.5% gross margin, indicating rapid commercial growth.
All but one of the 16 Sofwave reports are classified as injuries. The reported event types parallel Ultherapy's: burns, scarring, prolonged swelling, and contour irregularities. The 2025 cluster merits continued monitoring as Sofwave's installed base grows.
Sofwave markets its device as having "reported absence of adverse events in clinical trials" and positions its more superficial energy delivery as safer than Ultherapy's deeper approach. The MAUDE data suggests that while the clinical trial safety profile was clean, real-world use is generating reports at a rate that may accelerate as more providers adopt the platform.
Liposonix and UltraShape: body-contouring ultrasound
Liposonix (now discontinued) and UltraShape — focused ultrasound devices originally cleared for non-invasive fat reduction — account for 42 reports. Almost all (41 of 42) are injury reports.
| Year | Liposonix/UltraShape reports |
|---|---|
| 2012 | 1 |
| 2013 | 12 |
| 2014 | 3 |
| 2015 | 6 |
| 2016 | 8 |
| 2017 | 5 |
| 2018 | 3 |
| 2020 | 1 |
The Liposonix report volume peaked in 2013–2016 and has since tapered off, consistent with the device's market discontinuation. UltraShape reports are fewer but continue sporadically. Reported injuries include pain, swelling, burns, and contour irregularities in treated body areas.
Year-over-year trend: all ultrasound aesthetic devices
| Year | Total OHV reports |
|---|---|
| 2012 | 1 |
| 2013 | 18 |
| 2014 | 17 |
| 2015 | 19 |
| 2016 | 29 |
| 2017 | 29 |
| 2018 | 10 |
| 2019 | 15 |
| 2020 | 6 |
| 2021 | 19 |
| 2022 | 12 |
| 2023 | 12 |
| 2024 | 11 |
| 2025 | 21 |
| 2026 (Jan–May) | 4 |
The 2025 total of 21 reports represents the highest annual count since 2017, driven primarily by Sofwave's reporting surge and continued Ultherapy reports. The first five months of 2026 have already generated 4 reports, on pace for roughly 10 by year-end.
What patients should understand
Ultrasound energy is not trivial
These devices deliver focused ultrasound energy at intensities sufficient to cause thermal coagulation of tissue. That is how they work — controlled thermal injury triggers collagen remodeling. When the energy is delivered at the wrong depth, in the wrong location, or at excessive intensity, the result is not cosmetic improvement but tissue damage: fat atrophy, nerve injury, scarring, and burns.
The cleared indication matters
Ultherapy's cleared indications include brow lift, submental and neck lift, décolleté lines, and (as of November 2025 via Ultherapy PRIME) abdomen and arms. Sofwave is cleared for improving facial lines and wrinkles, and for upper arm laxity. When providers use these devices in areas outside the cleared indication — a practice that is legal but may carry different risk profiles — the clinical evidence base is thinner.
Provider experience is the critical variable
The MAUDE reports, the published literature, and the legal filings around Ultherapy injuries consistently point to provider factors as the primary driver of serious complications: incorrect depth settings, inadequate imaging (for Ultherapy's visualization system), failure to adjust energy for anatomic location, and insufficient training on the specific device. The same device in experienced hands produces far fewer complications than in inexperienced hands.
MAUDE underreports — the real number is higher
MAUDE is a passive surveillance system. Studies have estimated that adverse events captured in MAUDE represent a fraction of actual events — some analyses suggest 1–10% of real-world incidents, depending on the device type and reporting requirements. The 223 reports analyzed here likely represent hundreds of additional events that were never reported to the FDA.
Burns and fat loss can be permanent
Unlike hyaluronic acid filler complications — which can be reversed with hyaluronidase — thermal tissue damage from ultrasound devices is typically permanent. Fat atrophy may be partially correctable with filler or fat transfer, but the underlying tissue loss does not regenerate. Nerve damage may be temporary (resolving over weeks to months) or, in some cases, permanent.
What to ask before ultrasound skin tightening
- Is the device being used for an FDA-cleared indication in the area being treated?
- How many procedures has this provider performed with this specific device (not just skin treatments in general)?
- Will the provider use the device's imaging/visualization system to confirm energy delivery depth before firing?
- What happens if there is a complication? Does the clinic have a protocol and a supervising physician available?
- What are the realistic expectations for improvement, and what is the track record of dissatisfaction or complications?
Patients who experience unexpected pain, numbness, swelling, or visible contour changes after ultrasound treatment should report the event to the FDA through the MedWatch system and seek evaluation from a board-certified dermatologist or plastic surgeon.
Sources
- FDA MAUDE database — search by product code OHV: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfMAUDE/TextSearch.cfm
- Humphrey VS, Rambhia PH, Gmyrek R, Chapas A. Microfocused Ultrasound With Visualization: A Systematic Review of Adverse Events and Risk of Subsequent Facelift Compromise. Dermatol Surg. 2025;51(4):424-429. https://pubmed.ncbi.nlm.nih.gov/39625163
- FDA 510(k) database — Ulthera System clearances: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
- Sofwave corporate blog on safety positioning: https://sofwave.com/blog/a-strong-business-case-for-aesthetic-practices-sofwave
- FDA Dermal Fillers and Aesthetic Cosmetic Devices: https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices
Analysis sample: FDA MAUDE database extract dated 2026-06-10, 223 adverse event reports under product code OHV (Focused Ultrasound for Tissue Heat or Mechanical Cellular Disruption), received December 2012 through May 2026. Analysis by AestheticMedGuide.
